BI breathes easy after Spiriva trumps LABAs in old school German HTA
This article was originally published in Scrip
Executive Summary
Boehringer Ingelheim's top selling drug, Spiriva (tiotropium) offers additional benefit compared to placebo and long-acting beta-2 agonists (LABAs), says a report from IQWiG, Germany's Institute of Quality and Efficiency in Healthcare. The findings mark a more positive endorsement of the drug than the institute's previous report published in November, which concluded that Spiriva offered additional benefit in comparison only to one LABA, salmeterol.